(Total Views: 155)
Posted On: 03/12/2019 7:57:12 AM
Post# of 154930
Revenue isn’t expected until 2020.....but here’s how:
1) combo approval
2) sell leronlimab
Per independent study, combo market is 49,000 people (49,000 is based on extreme conservative numbers.....but full year). At $70,000 price point this is a little over 7,000 people (current price for R3 drug that has less efficacy and worse SAEs is $118,000/year).
They also have prostate prognostic test that has potential of up to $750,000,000 annual revenue. This is based on 250,000 test done annually at low end of current test at $3,000. This test is 5-8 times more accurate than any currently on the market.
1) combo approval
2) sell leronlimab
Per independent study, combo market is 49,000 people (49,000 is based on extreme conservative numbers.....but full year). At $70,000 price point this is a little over 7,000 people (current price for R3 drug that has less efficacy and worse SAEs is $118,000/year).
They also have prostate prognostic test that has potential of up to $750,000,000 annual revenue. This is based on 250,000 test done annually at low end of current test at $3,000. This test is 5-8 times more accurate than any currently on the market.
(0)
(0)
Please do your own due diligence. All my posts and comments are not to be considered investment advice.
